(Q35128436)

6 August 2017

1 reference

title

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis (English)

1 reference

6 August 2017

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80086-3

2 January 2024

author name string

Christopher McCoy

1

1 reference

6 August 2017

Samuel James Matthews

2

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12749504

2 January 2024

publication date

1 February 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0149291803800863?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80086-3

https://api.elsevier.com/content/article/PII:S0149291803800863?httpAccept=text/plain

2 January 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80086-3

2 January 2024

published in

Clinical Therapeutics

1 reference

6 August 2017

volume

25

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

396-421

1 reference

Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Adjunctive therapy for septic shock: a review of experimental approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Epidemiology of sepsis syndrome in 8 academic medical centers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Has the mortality of septic shock changed with time

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Current understanding of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Treating patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Studies on group B beta-hemolytic Streptococcus. I. Isolation and partial characterization of an extracellular toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Isolation and identification of the group B streptococcal toxin CM101 from infants with sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Sepsis: a new hypothesis for pathogenesis of the disease process

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Pathogenetic mechanisms of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Sepsis and serum cytokine concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

The endothelium in sepsis: source of and a target for inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Time course of hemostatic abnormalities in sepsis and its relation to outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Vascular-bed--specific hemostasis and hypercoagulable states

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Pathogenesis of disseminated intravascular coagulation in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Disseminated intravascular coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

APACHE II: a severity of disease classification system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Predictive value of severity scoring systems: comparison of four models in Tunisian adult intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Novel Asn-linked oligosaccharides terminating in GalNAc beta (1-->4)[Fuc alpha (1-->3)]GlcNAc beta (1-->.) are present in recombinant human protein C expressed in human kidney 293 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Protein C in the treatment of coagulopathy in meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Treatment of purpura fulminans in meningococcemia with protein C concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Human recombinant activated protein C in meningococcal sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Risks and benefits of activated protein C treatment for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Assessing the use of activated protein C in the treatment of severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980086-3

7 January 2021

Regulation and functions of the protein C anticoagulant pathway

46

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80086-3

Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate

2 January 2024

52

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80086-3

Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes

2 January 2024

54

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80086-3

2 January 2024

Identifiers

1 reference

6 August 2017

1 reference